Cash, cash equivalent and marketable securities were $12.7 million as of March 31, 2024, as compared to $16.8 million as of December 31, 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
- Gain Therapeutics announces results from SAD part of Phase 1 GT-02287 trial
- Gain Therapeutics Welcomes New CFO Gene Mack
- Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
- Gain Therapeutics appoints Gene Mack as CFO